American Society of Hematology

Newsroom

ASH, the world's largest professional society concerned with the causes and treatments of blood disorders, regularly issues press releases highlighting clinical and research advances announced at the ASH annual meeting and published in Blood, as well as releases and statements on breaking policy news affecting the field of hematology.

Need to speak with an expert? Complete our Request An Expert form.

To be added to ASH's press release distribution list, contact Sara Khalaf at skhalaf@hematology.org.

Latest Press Releases

  • Encouraging Results Seen with Novel Approach to Gene Therapy for Sickle Cell Disease Dec 10, 2019

    Three adult patients with sickle cell disease (SCD) are doing well after receiving an infusion of their own stem cells that had been genetically engineered to induce them to stop producing harmful “sickle” hemoglobin and start producing a healthy form of hemoglobin, according to a study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando.

  • New Drug Markedly Improves Overall Survival in Patients with AML in Remission Dec 10, 2019

    Using an investigational oral form of azacitidine therapy, CC-486, significantly improved overall survival in older patients with newly diagnosed acute myeloid leukemia (AML) who were in remission following standard induction chemotherapy with or without consolidation therapy, according to a phase III study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando.

  • Phase III Trial Finds Sutimlimab Effective Against Cold Agglutinin Disease Dec 10, 2019

    Patients with cold agglutinin disease (CAD) had improved hemoglobin levels, required fewer blood transfusions, and felt significantly less fatigued after receiving the experimental drug sutimlimab for 26 weeks in a phase III clinical trial.

View all